Targeting epigenetic enzymes for drug discovery
Authors:
- Robert A CopelandRCRobert A Copeland
- Edward J OlhavaEOEdward J Olhava
- Margaret Porter ScottMSMargaret Porter Scott
- 1 August 2010
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 14 (4) , 505-510
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Histone acetyl transferases as emerging drug targetsDrug Discovery Today, 2009
- Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)—Hit to Lead studiesBioorganic & Medicinal Chemistry Letters, 2009
- HDAC expression and clinical prognosis in human malignanciesCancer Letters, 2009
- Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)Bioorganic & Medicinal Chemistry Letters, 2009
- Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferasesBioorganic & Medicinal Chemistry Letters, 2009
- At the Flick of a Switch: Epigenetic DrugsChemistry & Biology, 2008
- Chromatin Modifications and Their FunctionCell, 2007
- The Epigenomics of CancerCell, 2007
- Histone H2B Monoubiquitination Functions Cooperatively with FACT to Regulate Elongation by RNA Polymerase IICell, 2006